Sotera Health (SHC) Q3 2026 Earnings Call Transcript

Sotera Health (SHC) reported Q3 2026 revenue growth of 4.4% to $325M and adjusted EBITDA growth of 4% to $171M. Sterigenics grew 8.2%, Nelson Labs 9.2%, and Nordion declined 11.5%. The company reaffirmed its 2026 revenue and adjusted EBITDA outlook, expecting 5.25-6.75% and 5.75-7.25% growth, respectively. Adjusted EBITDA margins expanded sequentially by 100 basis points to 52.5%.

Original reporting
Published Nov 3, 2026, 9:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sotera Health (SHC) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$SHCNeutralHigh
01

Why it matters

Earnings reaffirmation supports current valuation; no major surprises but solid execution may sustain current price levels.

02

Market read

First earnings report of the quarter; provides fresh data for traders to adjust positions.

03

What to watch

Potential softness in med device market could pressure Sterigenics segment later.

Relevance 8/10Novelty 9/10Timing: after-hours earnings release

Background

Sotera Health operates Sterigenics, Nelson Labs, and Nordion segments providing safety testing and sterilization services.

Company-level read

Ticker impact

$SHCNeutralHigh confidence
Context

Sotera Health disclosed Q3 2026 results with revenue $325M, EPS $0.20 and reaffirmed full-year guidance.

Expected impact

likely modest upside as market prices in solid growth and reaffirmed outlook

Evidence & confidence

First earnings release with fresh numbers; solid performance but no surprise guidance change.

Market effects

Positive for healthcare services and contract testing sector as earnings show resilience.

U.S. healthcare services stocks may see modest lift.

Limited to investors tracking US healthcare service providers.

Counterpoint

Guidance unchanged could signal limited growth; investors may wait for next quarter for upside.

Key entities

  • Sotera Health

    Provider of healthcare product safety and sterilization services.

Related articles

MedAI 8/10

Sotera Health Company Q3 2026 Earnings Call Summary

Sotera Health reported Q3 2026 earnings, with Sterigenics and Nelson Labs driving performance. Nordion saw revenue decline due to cobalt-60 timing. Management noted European market softness. Guidance reaffirmed, with flat Q4 Sterigenics revenue and reduced 2027 CapEx. Nelson Labs' growth expected to moderate. Net leverage improved to 2.9x, leading to a credit rating upgrade. Litigation and FX headwinds noted.

$SHCHighAI 8/10

Why is Sotera Health stock sliding today?

Sotera Health (SHC) shares fell 9.5% despite Q3 2026 earnings beat (EPS $0.29, revenue $324.9M) due to cautious guidance. Revenue declined 12% in the Nordion segment. JPMorgan downgraded to Underweight with a $17 target, and insiders sold 1.29M shares. The S&P 500 and Nasdaq rose, but Sotera's decline was company-specific.

$SHCMed

What Sotera Health (SHC) Said on Its Q3 Earnings Call

Sotera Health (SHC) reported Q3 earnings, noting softness in the European medical-device market. Sterigenics expects 6% constant-currency growth in Q4, while Nelson Labs saw 8.8% revenue growth. Nordion revenue fell 12.4% due to shipment timing. The company reaffirmed its 2026 outlook for 5.25% to 6.75% revenue growth and maintained its adjusted EBITDA forecast.